In re: Patent Application of YOKOI et al Serial No. 09/680,514

IN THE CLAIMS:

Amend the claims as follows:

10. (Amended) A fusion polypeptide which comprises a human granulocyte colony stimulating factor polypeptide and c-mpl ligand polypeptide and has no mouse IL-3 activity as measured by inability to stimulate growth of Ba/F3 cells, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence in which the amino acid nos. 155 to 327 of the amino acid sequence shown in SEQ ID NO:1 is replaced by an amino acid sequence selected from an amino acid sequence represented in Table 1 and Table 2 a) to j) and l).

the human granulocyte colony stimulating factor polypeptide is fused via a spacer peptide to the c-mpl ligand polypeptide.

12. (Amended) The fusion polypeptide according to claim 11, wherein the polypeptide is selected from a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:3, an amino acid sequence in which the amino acid nos. 167 to 340 of the amino acid sequence shown in SEQ

695370

In re: Patent Application of YOKOI et al Serial No. 09/680,514

ID NO:2 is replaced by an amino acid sequence selected from the amino acid sequences represented in Table 1 and Table 2 a) to j) and l), and an amino acid sequence in which the amino acid nos. 171 to 344 of the amino acid sequence shown in SEQ ID NO: 3 is replaced by an amino acid sequence selected from the amino acid sequences represented in Table 1 and Table 2 a) to j) and l).

REMARKS

Reconsideration is requested.

Claims 10-18 are pending. Claims 16-18 have been withdrawn from consideration.

The specification has been amended to correct the reference to the serial number of the parent application. No new matter has been added.

The applicants affirm the election of Mr. Crawford, made with traverse, of the subject matter of the Examiner's Group I, for prosecution in the above. Reconsideration and withdrawal of the restriction requirement are requested as examination of all the pending claims is not believed, with all due respect, to present an undue burden on the Examiner.